Floatz logo

Linvoseltamab

Waldenstrom Macroglobulinaemia

Anne Louise Tølbøll SørensenPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

59 Active assets in the Waldenstrom Macroglobulinaemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BBB
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BBB
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
PREDNISONE TABLETS
BeOne Medicines
Phase 2BBB
Inno-206
BeOne Medicines
Phase 2BBB

View all 50 →

Same molecule, other indications

Linvoseltamab is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
66 / 100
View asset →
smoldering plasma cell myelomaDormant
BB
Indicative ·
66 / 100
View asset →
monoclonal gammopathy of uncertain significanceDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →